# Telik clinical trials: 21 on ClinicalTrials.gov (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 21 trials with Telik as lead sponsor, 0 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Telik: 21 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/company/telik

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 21
- Recruiting or not yet: 0
- Read on: November 19, 2026

## Trials

The 21 newest of 21, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| October 25, 2011 | NCT01459159 | Study of (Telintra®) in Non-Del(5q) Myelodysplastic Syndrome | Telik | Phase 2 | Terminated | Myelodysplastic Syndrome (MDS) | 162 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01459159) |
| August 24, 2011 | NCT01422486 | Phase 2 Study of Telintra® in Deletion 5q Myelodysplastic Syndrome | Telik | Phase 2 | Terminated | Myelodysplastic Syndrome (MDS) | 2 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01422486) |
| June 22, 2010 | NCT01148108 | Study of Canfosfamide in Refractory or Relapsed Mantle Cell, Diffuse Large B Cell Lymphoma and Multiple Myeloma | Telik | Phase 2 | Completed | Mantle Cell Lymphoma, B Cell Lymphoma, Multiple Myeloma | 14 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01148108) |
| February 4, 2010 | NCT01062152 | Dose-Ranging Study of Telintra® Tablets + Revlimid® in Patients With Non-Deletion (5q) Low to Intermediate-1 Risk Myelodysplastic Syndrome... | Telik | Phase 1 | Completed | Myelodysplastic Syndrome | 19 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01062152) |
| May 28, 2009 | NCT00909584 | Study of Ezatiostat (Telintra Tablets) for Treatment of Severe Chronic Neutropenia | Telik | Phase 2 | Terminated | Severe Chronic Neutropenia | 9 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00909584) |
| June 19, 2008 | NCT00701870 | Study of Telintra for Treatment of Chemotherapy Induced Neutropenia in Patients With Non-Small Cell Lung Cancer | Telik | Phase 2 | Terminated | Non-small Cell Lung Cancer | 1 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00701870) |
| June 18, 2008 | NCT00700206 | Phase 2 Study Comparing Two Dose Schedules of Telintra™ in Myelodysplastic Syndrome (MDS) | Telik | Phase 2 | Completed | Myelodysplastic Syndrome (MDS) | 86 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00700206) |
| July 11, 2006 | NCT00350948 | Phase 3 Randomized Study of Telcyta + Doxorubicin Versus Doxorubicin in Platinum Refractory or Resistant Ovarian Cancer | Telik | Phase 3 | Terminated | Ovarian Neoplasms | 244 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00350948) |
| January 23, 2006 | NCT00280631 | Study of TLK199 Tablets in Myelodysplastic Syndrome (MDS) | Telik | Phase 1/2 | Completed | Myelodysplastic Syndrome (MDS) | 49 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00280631) |
| February 7, 2005 | NCT00102973 | TLK286 (Telcyta) in Combination With Carboplatin (Paraplatin) Versus Doxil in Platinum Refractory or Resistant Ovarian Cancer | Telik | Phase 3 | Completed | Ovarian Neoplasms | 244 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00102973) |
| July 30, 2004 | NCT00088556 | Carboplatin, Paclitaxel and TLK286 (Telcyta) as First-Line Therapy in Advanced Non-Small Cell Lung Cancer | Telik | Phase 1/2 | Completed | Carcinoma, Non-Small-Cell Lung | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00088556) |
| March 30, 2004 | NCT00080340 | Study of TLK286 (Telcyta) vs. Gefitinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer | Telik | Phase 3 | Completed | Non Small Cell Lung Carcinoma | 520 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00080340) |
| February 16, 2004 | NCT00077883 | TLK286 (Telcyta) in Combination With Cisplatin for Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) | Telik | Phase 1/2 | Completed | Non-small Cell Lung Cancer | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00077883) |
| April 8, 2003 | NCT00057720 | TLK286 (Telcyta) vs. Doxil/Caelyx or Hycamtin in Platinum Refractory or Resistant Ovarian Cancer | Telik | Phase 3 | Completed | Ovarian Neoplasms | 440 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00057720) |
| January 23, 2003 | NCT00052065 | TLK286 in Combination With Doxil in Platinum Refractory or Resistant Ovarian Cancer | Telik | Phase 1/2 | Completed | Ovarian Neoplasms | 28 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00052065) |
| January 22, 2003 | NCT00051948 | TLK286 in Combination With Paraplatin (Carboplatin) in Recurrent Ovarian Cancer | Telik | Phase 1/2 | Completed | Ovarian Neoplasms | 28 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00051948) |
| October 21, 2002 | NCT00047801 | Phase 1-2a Dose-Ranging Study of TLK286 in Combination With Docetaxel in Platinum-Resistant Non-Small Cell Lung Cancer | Telik | Phase 1/2 | Completed | Carcinoma, Non-small-cell Lung | 28 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00047801) |
| July 4, 2002 | NCT00040638 | Phase 2 Study of TLK286 Administered Weekly in Advanced Non-Small Cell Lung Cancer | Telik | Phase 2 | Completed | Carcinoma, Non-small-cell Lung | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00040638) |
| May 31, 2002 | NCT00038428 | Phase 2 Study of TLK286 in Platinum Resistant Advanced Epithelial Ovarian Cancer | Telik | Phase 2 | Completed | Ovarian Neoplasms | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00038428) |
| May 7, 2002 | NCT00035867 | Study of TLK199 HCl Liposomes for Injection in Myelodysplastic Syndrome | Telik | Phase 1/2 | Completed | Myelodysplastic Syndromes | 65 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00035867) |
| May 7, 2002 | NCT00035841 | Phase 2 Study of TLK286 in Metastatic Breast Cancer | Telik | Phase 2 | Completed | Breast Neoplasms | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00035841) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 1 |
| Phase 1/2 | 7 |
| Phase 2 | 9 |
| Phase 3 | 4 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 16 |
| Terminated | 5 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Ovarian Neoplasms | 6 |
| Carcinoma, Non-Small-Cell Lung | 6 |
| Myelodysplastic Syndromes | 6 |
| Lymphoma, Mantle-Cell | 1 |
| Lymphoma, B-Cell | 1 |
| Multiple Myeloma | 1 |
| Lymphoma, Non-Hodgkin | 1 |
| Lymphoma | 1 |
| Neutropenia, severe chronic | 1 |
| Neutropenia | 1 |
| Breast Neoplasms | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Prosthetics providers in the United States](https://specstream.ai/data/businesses/prosthetics-providers/united-states)
- [Apparel manufacturers in the United States](https://specstream.ai/data/businesses/apparel-manufacturers/united-states)
- [Ecuadorian restaurants in the United States](https://specstream.ai/data/businesses/ecuadorian-restaurants/united-states)
- [Masonry contractors in the United States](https://specstream.ai/data/businesses/masonry-contractors/united-states)
- [Steakhouses in the United States](https://specstream.ai/data/businesses/steakhouses/united-states)
- [Boat and ship manufacturers in the United States](https://specstream.ai/data/businesses/boat-and-ship-manufacturers/united-states)
